Arbutus Biopharma Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016      No Of Pages (40)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Arbutus Biopharma-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Arbutus. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in prclinical phase. There is 1 cancer drug by Arbutus Biopharma which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Arbutus Biopharma-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Arbutus Biopharma-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Arbutus. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in prclinical phase. There is 1 cancer drug by Arbutus Biopharma which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Arbutus Biopharma-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Arbutus Biopharma

  1.1 Business Overview

  1.2 Arbutus Biopharma Cancer Pipeline Overview

 

2. Arbutus Biopharma Cancer Drugs in Research Phase

  2.1 siRNA Anticancer Therapeutics - Bristol-Myers Squibb/Arbutus

 

3. Arbutus Biopharma Cancer Drugs in Preclinical Phase

  3.1 RNAi Therapeutics – Arbutus

  3.2 Dicer-Substrate siRNA Therapeutics – Dicerna

  3.3 Systemic RNAi Therapeutics - Alnylam/Arbutus Biopharma

 

4. Arbutus Biopharma Cancer Drugs in Phase-I

  4.1 ALN VSP

 

5. Arbutus Biopharma Cancer Drugs in Phase I/II

  5.1 TKM PLK1

 

6. Marketed Cancer Drugs by Arbutus Biopharma

  6.1 Vincristine Liposomal (Marqibo)

 

7. No Development Reported in Cancer Drugs in Clinical Pipeline

  7.1 Topotecan Liposomal - Spectrum Pharmaceuticals

 

8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 ARB 1598

  8.2 Pro 1

  8.3 SPLP Gene Therapies – Protiva

  8.4 TCS Gene Delivery Systems - Inex Pharmaceuticals/Protiva Biotherapeutics

 

9. Suspended in Cancer Drug in Clinical Pipeline

  9.1 Vinorelbine Liposomal - Spectrum Pharmaceuticals


Figure 1-1: Arbutus Biopharma Cancer Pipeline by Phase (%)

Figure 1-2: Arbutus Biopharma Cancer Pipeline by Phase (Number)

Figure 1-3: Arbutus Biopharma Cancer Pipeline by Phase (%)

Figure 1-4: Arbutus Biopharma Cancer Pipeline by Phase (Number)